Winton Group’s Context Therapeutics CNTX Stock Holding History

Winton Group’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-81,303	Closed	-$213K	–	1224
2026 Q1	$213K	Buy	+81,303	New	+$190K	0.01%	964

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Winton Group's CNTX Position: Q2 2026 in Review

Winton Group sold out of Context Therapeutics (CNTX) in Q2 2026, closing a stake of 81,303 shares — an estimated $213K sold.

Winton Group first reported a position in CNTX in Q1 2026 and held it in 1 quarter. The position peaked at $213K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Winton Group reported no remaining Context Therapeutics position as of Q2 2026 after selling out during the quarter.
Winton Group sold 81,303 Context Therapeutics shares in Q2 2026, an estimated $213K.
Winton Group first reported a position in Context Therapeutics in Q1 2026 and held it in 1 quarter.
Winton Group's Context Therapeutics position peaked at $213K in Q1 2026.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.